Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Rani Therapeutics Holdings, Inc.
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/11/2023
8-K
Quarterly results
Docs:
"
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association’s Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1study for RT-111 in 2H of 2023 SAN JOSE, Calif., August 11, 2023
"
05/10/2023
8-K
Quarterly results
Docs:
"
Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2H of 2023 - SAN JOSE, Calif., May 10, 2023
"
04/05/2023
8-K
Other Events Interactive Data
03/22/2023
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
"
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar - - Conference call and webcast today at 4:30 p.m. ET - SAN JOSE, Calif., March 22, 2023
"
01/09/2023
8-K
Entry into a Material Definitive Agreement Interactive Data
01/05/2023
8-K
Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...
Docs:
"
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update - Preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis - SAN JOSE, Calif., January 5, 2023
"
12/30/2022
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
12/06/2022
8-K
Investor presentation
Docs:
"
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability - - Data from Part 1 and Part 2 of the Phase 1study of RT-102 support advancement to a Phase 2 study – SAN JOSE, Calif., December 6, 2022
",
"
RT-102 Phase I Study
"
10/24/2022
8-K
Quarterly results
08/25/2022
8-K
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Controlled EquitySM Sales Agreement, by and among Rani Therapeutics Holdings, Inc., and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC
",
"
Opinion of Cooley LLP
"
08/10/2022
8-K
Quarterly results
Docs:
"
Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations into mid-2024 - SAN JOSE, Calif., August 10, 2022
"
08/08/2022
8-K
Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
"
FORM 8-K
"
05/26/2022
8-K
Quarterly results
05/11/2022
8-K
Quarterly results
03/29/2022
8-K
Quarterly results
03/23/2022
8-K
Quarterly results
02/23/2022
8-K
Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Rani Therapeutics Unveils High-Capacity RaniPill ™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results
",
"
Presentation dated February 2022
"
01/05/2022
8-K
Appointed a new director
11/12/2021
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
"
09/29/2021
8-K
Quarterly results
09/13/2021
8-K
Quarterly results
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy